- Home
- ALNY vs SW Comparison
ALNY vs SW Comparison
Compare ALNY & SW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- SW
- Stock Information
- Founded
- ALNY 2002
- SW 1934
- Country
- ALNY United States
- SW Ireland
- Employees
- ALNY N/A
- SW N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- SW
- Sector
- ALNY Health Care
- SW
- Exchange
- ALNY Nasdaq
- SW Nasdaq
- Market Cap
- ALNY 33.2B
- SW 27.5B
- IPO Year
- ALNY 2004
- SW N/A
- Fundamental
- Price
- ALNY $264.99
- SW $54.99
- Analyst Decision
- ALNY Buy
- SW Buy
- Analyst Count
- ALNY 24
- SW 9
- Target Price
- ALNY $299.09
- SW $60.56
- AVG Volume (30 Days)
- ALNY 643.5K
- SW 3.0M
- Earning Date
- ALNY 02-13-2025
- SW 02-19-2025
- Dividend Yield
- ALNY N/A
- SW 2.22%
- EPS Growth
- ALNY N/A
- SW N/A
- EPS
- ALNY N/A
- SW 0.68
- Revenue
- ALNY $2,094,795,000.00
- SW $16,432,000,000.00
- Revenue This Year
- ALNY $24.87
- SW $139.92
- Revenue Next Year
- ALNY $18.53
- SW $14.64
- P/E Ratio
- ALNY N/A
- SW $77.92
- Revenue Growth
- ALNY 21.54
- SW 27.83
- 52 Week Low
- ALNY $141.98
- SW $38.55
- 52 Week High
- ALNY $304.39
- SW $56.99
- Technical
- Relative Strength Index (RSI)
- ALNY 61.89
- SW N/A
- Support Level
- ALNY $245.69
- SW N/A
- Resistance Level
- ALNY $256.93
- SW N/A
- Average True Range (ATR)
- ALNY 9.38
- SW 0.00
- MACD
- ALNY 2.95
- SW 0.00
- Stochastic Oscillator
- ALNY 99.91
- SW 0.00
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About SW Smurfit WestRock plc Ordinary Shares
Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.